Anbio Biotechnology

Anbio Biotechnology (NASDAQ: NNNN) is an in-vitro diagnostics (IVD) company providing laboratory and point-of-care testing instruments and assays — lateral flow and fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), SHA dry chemistry, chemiluminescence immunoassay, and real-time PCR — across the European Union, Asia Pacific, North America, and South America, including SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. Incorporated in 2021 and based in Frankfurt am Main, Germany, the company listed Class A ordinary shares on Nasdaq in February 2025 and files with the SEC as a foreign private issuer (20-F).